Interindividual variability in P450-dependent generation of neoantigens in halothane hepatitis.
Halothane hepatitis occurs because susceptible patients mount immune responses to trifluoroacetylated protein antigens, formed following cytochrome P450-mediated bioactivation of halothane to trifluoroacetyl chloride. In the present study, an in vitro approach has been used to investigate the cytochrome P450 isozyme(s) which catalyze neoantigen formation and to explore the protective role of non-protein thiols (cysteine and reduced glutathione). Significant levels of trifluoroacetyl protein antigens were generated when human liver microsomes, and also microsomes from livers of rats pre-treated with isoniazid, phenobarbital or beta-naphtoflavone, were incubated with halothane plus a nicotinamide adenine dinucleotidephosphate (NADPH) generating system. Immunoblotting studies revealed that the major trifluoroacetyl antigens expressed in vitro exhibited molecular masses of 50-55 kDa and included 60 and 80 kDa neoantigens recognized by antibodies from patients with halothane hepatitis. Much lower concentrations of halothane were required to produce maximal antigen generation in isoniazid-induced rat microsomes, as compared with phenobarbital or isosafrole-induced microsomes (0.5 vs 12.5 microl/ml). In isoniazid-induced microsomes, antigen generation was inhibited > 90% by the nucleophiles cysteine and glutathione and by the CYP2E1-selective inhibitors diallylsulfide and p-nitrophenol, but was unaffected by inhibitors of other P450 isozymes (furafylline, sulfaphenazole or triacetyloleandomycin). Neoantigen formation in six human liver microsomal preparations was inhibited in the presence of diallylsulfide, but not by furafylline, sulfaphenazole or triacetyloleandomycin, and exhibited marked variability which correlated with CYP2E1 levels. These results suggest that the balance between metabolic bioactivation by CYP2E1 and detoxication of reactive metabolites by cellular nucleophiles could be an important metabolic risk factor in halothane hepatitis.
Eliasson
E
E
Department of Molecular Toxicology, Imperial College School of Medicine at St Mary's, London, UK. erieli@ki.se
Gardner
I
I
Hume-Smith
H
H
de Waziers
I
I
Beaune
P
P
Kenna
J G
JG
D000818:Animals; D056486:Chemical and Drug Induced Liver Injury / Q000201:enzymology / Q000276:immunology / Q000378:metabolism*; D062845:Chloroacetates; D003545:Cysteine / Q000378:metabolism; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism*; D004789:Enzyme Activation / Q000187:drug effects; D005978:Glutathione / Q000378:metabolism; D006221:Halothane / Q000493:pharmacokinetics / Q000633:toxicity*; D018963:Hepatitis Antigens / Q000096:biosynthesis*; D008658:Inactivation, Metabolic; D007206:Individuality; D007527:Isoenzymes / Q000378:metabolism*; D008297:Male; D008862:Microsomes, Liver / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D010455:Peptides / Q000276:immunology / Q000378:metabolism; D011817:Rabbits; D051381:Rats; D011916:Rats, Inbred F344; D017207:Rats, Sprague-Dawley; D014238:Trichloroacetic Acid / Q000493:pharmacokinetics
D062845:Chloroacetates; D018963:Hepatitis Antigens; D007527:Isoenzymes; D010455:Peptides; D014238:Trichloroacetic Acid; D003577:Cytochrome P-450 Enzyme System; C037540:trichloroacetyl chloride; D005978:Glutathione; D003545:Cysteine; D006221:Halothane